No Data
Express News | HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $5 Price Target
Cognition Therapeutics Analyst Ratings
Positive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition Therapeutics
Cognition Therapeutics Provided an Update on Phase 2 'SHINE' Study Analysis
Express News | Cognition Therapeutics Inc -Topline Results in Second Dementia Indication Expected to Be Reported in December 2024
Express News | Cognition Therapeutics Announces All Participants Have Completed Their Final Visits in the Phase 2 Shimmer Study of Ct1812 in Dementia With Lewy Bodies
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}